The impact of remdesivir on renal and liver functions in severe
COVID-19 patients with presence of viral load

J 2025

The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load

WALDAUF, Petr; Ivana JURISINOVA; Eva SVOBODOVA; Michaela DIBLICKOVA; Tomas TENCER et al.

Základní údaje

Originální název

The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load

Autoři

Vydání

Scientific Reports, Berlin, NATURE RESEARCH, 2025, 2045-2322

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30303 Infectious Diseases

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.900 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1038/s41598-025-05541-9

UT WoS

001522991900039

EID Scopus

2-s2.0-105009621841

Klíčová slova anglicky

Remdesivir; SARS-CoV-2; Viral load; Renal function; Liver function tests; Intensive care

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 8. 2025 08:01, Mgr. Tereza Miškechová

Anotace

V originále

The impact of remdesivir on renal and liver functions remains a matter of concern in advanced COVID-19 patients with high illness severity and presence of viral load. The laboratory results of the 114 patients (males 55.8%, age 71 (59; 77) years) with a detectable viral load treated with remdesivir were compared with the controls. Baseline plasmatic creatinine (PCr) < 150 mol/l in patients on remdesivir decreased equally to controls (- 6 (- 20; 9) vs. - 8 (- 24; 2) mu mol/l, n = 170, p = 0.11). The similar trends were found for baseline PCr >= 150 mu mol/l (- 57 (- 129; - 15) mu mol/l for remdesivir group vs. - 65 (- 111; - 7) mu mol/l, p > 0.9). Changes of PCr were independent of the remdesivir therapy, the statistically significant confounders were baseline PCr levels (p < 0.001), hospital length-of-stay (p < 0.001), leukocyte-to-lymphocyte ratio (p = 0.025). The plasmatic urea (PU) mildly increased in the remdesivir group (1 (- 2; 5) mmol/l vs. 0 (- 3; 2) mmol/l in the controls, p = 0.009), its levels were related to remdesivir (p = 0.026), age (p = 0.002), PCr (p < 0.001), hospital length-of-stay (p < 0.001), IPPV (p = 0.035). Regarding the liver function tests the significant relationships to remdesivir therapy were found only for GGT (p = 0.007) and ALT (p = 0.044). The levels of PCr were decreasing over the hospitalisation period including patients with mild-to-moderate renal insufficiency. The multivariate regression analysis excluded an impact of remdesivir on the PCr changes yet admitted an impact on the levels of urea, GGT and ALT.

Citovat

WALDAUF, Petr; Ivana JURISINOVA; Eva SVOBODOVA; Michaela DIBLICKOVA; Tomas TENCER; Jan ZAVORA; Gabriela SMELA; Lenka KUPIDLOVSKA; Vaclava ADAMKOVA; Marta FRIDRICHOVA; Karolina JERABKOVA; Jakub MIKES; Frantisek DUSKA; Ladislav DUŠEK a Martin BALIK. The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load. Scientific Reports. Berlin: NATURE RESEARCH, 2025, roč. 15, č. 1, s. 1-8. ISSN 2045-2322. Dostupné z: https://doi.org/10.1038/s41598-025-05541-9.

@article{2511398,
   author = {Waldauf, Petr and Jurisinova, Ivana and Svobodova, Eva and Diblickova, Michaela and Tencer, Tomas and Zavora, Jan and Smela, Gabriela and Kupidlovska, Lenka and Adamkova, Vaclava and Fridrichova, Marta and Jerabkova, Karolina and Mikes, Jakub and Duska, Frantisek and Dušek, Ladislav and Balik, Martin},
   article_location = {Berlin},
   article_number = {1},
   doi = {https://doi.org/10.1038/s41598-025-05541-9},
   keywords = {Remdesivir; SARS-CoV-2; Viral load; Renal function; Liver function tests; Intensive care},
   language = {eng},
   issn = {2045-2322},
   journal = {Scientific Reports},
   title = {The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load},
   url = {https://www.nature.com/articles/s41598-025-05541-9},
   volume = {15},
   year = {2025}
}

TY  - JOUR
ID  - 2511398
AU  - Waldauf, Petr - Jurisinova, Ivana - Svobodova, Eva - Diblickova, Michaela - Tencer, Tomas - Zavora, Jan - Smela, Gabriela - Kupidlovska, Lenka - Adamkova, Vaclava - Fridrichova, Marta - Jerabkova, Karolina - Mikes, Jakub - Duska, Frantisek - Dušek, Ladislav - Balik, Martin
PY  - 2025
TI  - The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load
JF  - Scientific Reports
VL  - 15
IS  - 1
SP  - 1-8
EP  - 1-8
PB  - NATURE RESEARCH
SN  - 20452322
KW  - Remdesivir
KW  - SARS-CoV-2
KW  - Viral load
KW  - Renal function
KW  - Liver function tests
KW  - Intensive care
UR  - https://www.nature.com/articles/s41598-025-05541-9
N2  - The impact of remdesivir on renal and liver functions remains a matter of concern in advanced COVID-19 patients with high illness severity and presence of viral load. The laboratory results of the 114 patients (males 55.8%, age 71 (59; 77) years) with a detectable viral load treated with remdesivir were compared with the controls. Baseline plasmatic creatinine (PCr) < 150 mol/l in patients on remdesivir decreased equally to controls (- 6 (- 20; 9) vs. - 8 (- 24; 2) mu mol/l, n = 170, p = 0.11). The similar trends were found for baseline PCr >= 150 mu mol/l (- 57 (- 129; - 15) mu mol/l for remdesivir group vs. - 65 (- 111; - 7) mu mol/l, p > 0.9). Changes of PCr were independent of the remdesivir therapy, the statistically significant confounders were baseline PCr levels (p < 0.001), hospital length-of-stay (p < 0.001), leukocyte-to-lymphocyte ratio (p = 0.025). The plasmatic urea (PU) mildly increased in the remdesivir group (1 (- 2; 5) mmol/l vs. 0 (- 3; 2) mmol/l in the controls, p = 0.009), its levels were related to remdesivir (p = 0.026), age (p = 0.002), PCr (p < 0.001), hospital length-of-stay (p < 0.001), IPPV (p = 0.035). Regarding the liver function tests the significant relationships to remdesivir therapy were found only for GGT (p = 0.007) and ALT (p = 0.044). The levels of PCr were decreasing over the hospitalisation period including patients with mild-to-moderate renal insufficiency. The multivariate regression analysis excluded an impact of remdesivir on the PCr changes yet admitted an impact on the levels of urea, GGT and ALT.
ER  -

WALDAUF, Petr; Ivana JURISINOVA; Eva SVOBODOVA; Michaela DIBLICKOVA; Tomas TENCER; Jan ZAVORA; Gabriela SMELA; Lenka KUPIDLOVSKA; Vaclava ADAMKOVA; Marta FRIDRICHOVA; Karolina JERABKOVA; Jakub MIKES; Frantisek DUSKA; Ladislav DUŠEK a Martin BALIK. The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load. \textit{Scientific Reports}. Berlin: NATURE RESEARCH, 2025, roč.~15, č.~1, s.~1-8. ISSN~2045-2322. Dostupné z: https://doi.org/10.1038/s41598-025-05541-9.

Přehled o publikaci